523 results
Updates in tricuspid TEER
21 May 2026 – From EuroPCR 2026
This session offers comprehensive updates on transcatheter edge-to-edge repair (TEER) for tricuspid valve disease. It reviews meta-analyses on outcomes in patients with cardiac implantable electronic device leads, long-term trial results, echocardiographic and clinical outcomes, right ventricular mechanics, risk scoring, and the impact of renal function and...
Structural heart devices: what's new and how it reaches your cathlab
20 May 2026 – From EuroPCR 2026
Discover the latest innovations in structural heart devices, spanning new TAVR platforms, mitral and tricuspid valve technologies, leaflet modification, and closure devices. Gain insight into the comprehensive innovation pathway from concept and prototyping to regulatory approval and clinical adoption, with perspectives from physician-innovators on drivers of...
Beyond the horizon - Future of structural heart innovations and PCI
20 May 2026 – From EuroPCR 2026
Structural heart and coronary interventions are expanding rapidly, with innovation increasingly focused on managing complex anatomies and diversifying treatment strategies.
The PRISM-PCI toolkit is introduced as a framework to support decision-making in complex PCI, alongside advances in transcatheter valve therapies spanning mitral, tricuspid and pulmonary interventions, as...
Seeing differently, treating better: advanced imaging shaping modern structural heart practice
20 May 2026 – From EuroPCR 2026
This session explores the transformative role of advanced imaging, particularly 3D intracardiac echocardiography (ICE), in modern structural heart interventions. It provides practical insights into implementation, highlighting how these tools can enhance workflow efficiency and procedural confidence across transcatheter edge-to-edge repair (TEER), left atrial appendage (LAA) closure,...
Beyond visualisation: the value and future of 4D intracardiac echocardiography in tricuspid repair and replacement
20 May 2026 – From EuroPCR 2026
Explore the transformative role of 4D intracardiac echocardiography in guiding tricuspid edge-to-edge repair (TEER) and valve replacement for tricuspid regurgitation. This session highlights how real-time, high-resolution imaging enhances procedural efficiency and safety, reducing reliance on general anesthesia and shortening procedure times compared to traditional imaging modalities.
Images that speak for themselves
20 May 2026 – From EuroPCR 2026
This visually-driven session presents compelling clinical cases where imaging played a decisive role. Cases include unexpected challenges following transcatheter tricuspid valve replacement, severe hypertension in a young athlete, atypical coronary artery anatomy, critical moments of cardiac arrest, and unique coronary artery findings resembling a spider web.
Tricuspid interventions: find the best candidate
20 May 2026 – From EuroPCR 2026
This session reviews the phenotypes of tricuspid regurgitation and their diagnostic pathways, emphasizing standardized and pragmatic diagnostic steps. It also addresses criteria for identifying optimal timing and candidates for tricuspid valve interventions.
Other valvular and structural interventions
20 May 2026 – From EuroPCR 2026
Covering a spectrum of valvular and structural heart interventions, this session discusses systemic aortic valve TEER in complex congenital cases, compares TAVI and surgical AVR outcomes via meta-analysis, highlights radiation protection advances in complex endovascular repair, and presents combined mitral and tricuspid TEER techniques, novel ultrasound...
Other right-sided and tricuspid valve interventions
20 May 2026 – From EuroPCR 2026
This session focuses on right-sided heart valve interventions, particularly targeting tricuspid valve disease. Topics include clinical outcomes in atrial functional tricuspid regurgitation, management in the context of left-sided valvular disease, treatment approaches for tricuspid valve endocarditis, and advances in transcatheter therapies and device placements.
When less is better - Differentiated therapies to safely achieve TR 0-1+
19 May 2026 – From EuroPCR 2026
Therapeutic goals in tricuspid regurgitation are evolving, with increasing emphasis on achieving near-complete elimination of regurgitation (TR 0–1+) through differentiated transcatheter strategies.
This EuroPCR 2026 session explores how transcatheter edge-to-edge repair (TEER) and transcatheter tricuspid valve replacement (TTVR) can be used in a complementary way to reach...
